NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Replicate Bioscience

Replicate Bioscience

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://replicatebioscience.com/

Last Round

Grant

Jun 19, 2026

Total Funding Raised

$49M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Replicate Bioscience is a biotechnology company that develops self-replicating RNA (srRNA) immunotherapies for the treatment of cancer, infectious diseases, and autoimmune disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

self-replicating RNAsrRNAsrRNA platformRNA therapeuticsimmunotherapiesnext-generation RNAcancer immunotherapyRNA vaccinegenomic medicinesautoimmune therapiesinfectious disease vaccinelow-dose therapeuticsdrug discovery platformpharmaceutical licensingclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Replicate Bioscience Comparables

Compare Replicate Bioscience with similar companies based on industry and business-model similarity.

Replicate Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Chimeron Bio
83%
Strand Therapeutics
83%
Bristol Myers Squibb
82%

Replicate Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 19, 2026
Series ASep 8, 2021
SeedFeb 16, 2021
SeedJun 24, 2020

Key People

Founding team and executive leadership

Andy Geall

Co-founder And Chief Development Officer

Founding Team

Nathaniel Wang

Chief Executive Officer and Co-Founder

Founding Team

Replicate Bioscience Investors

Notable investors and investment history

Replicate Bioscience investors
InvestorRounds
Apple Tree PartnersSeries A, Seed
Gates FoundationGrant
Bill & Melinda Gates FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2026

    Secured $7M in grant funding.

  • Jan 8, 2026

    Developing self-replicating RNA vaccines for HIV and malaria.

Replicate Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Replicate Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Replicate Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range22
Year Founded2020
Last FundingJun 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.